Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Motesanib Fails to Increase OS in Non-SCC NSCLC in PIII
April 18, 2011
- EPS to Establish Wholly Owned Subsidiary in South Korea
April 18, 2011
- APA Elevates Gastric pH in PI Trial: RaQualia
April 18, 2011
- Quintiles to Expand Tokyo Laboratory
April 18, 2011
- Olmesartan + CCB Suppress CV Events in Hypertensive Patients with a History of CV Disease
April 18, 2011
- Baxter Announces Change in Storage Temperature for Advate
April 18, 2011
- Valsartan, CCB Show Similar CV Events
April 18, 2011
- JP 16th Edition Published with 106 More Drugs Added
April 18, 2011
- Korosho Announces New Schedule for NHI Price Listing
April 18, 2011
- Ethical Drug Sales Up 6.1% in February: Crecon Research & Consulting
April 18, 2011
- Takeda Accelerating Tie-ups in CNS Field
April 18, 2011
- Pharmacists to Participate in Dispensing Bill Review Starting in June
April 18, 2011
- Domestic Generics-only Makers to Maintain Lead in GE Drug Market: Report
April 18, 2011
- DSP, BBI Enter Strategic Partnership on Anticancer Drugs
April 18, 2011
- Regulatory Reform Shelves Online Sale of OTC Drugs, Unification of Basic Dispensing Fees
April 18, 2011
- Nippon Chemiphar Introduces MR Team System on a Full Scale
April 18, 2011
- Eisai Reorganizes Its Businesses in East Asia
April 18, 2011
- Korosho Draws Up New GL for Clinical Evaluation of Drugs for Heart Failure
April 18, 2011
- Sawai's Cetirizine OD Tab Receives Generic Drug of Year Award
April 18, 2011
- Aftershocks Disrupt Production at Some Pharma Production Facilities
April 18, 2011
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…